Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hikma Pharmaceuticals Plc ADR (OP: HKMPY )

47.50 +0.77 (+1.65%)
Streaming Delayed Price Updated: 1:02 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 903
Open 47.50
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 46.73
Today's Range 47.50 - 47.50
52wk Range 42.23 - 55.56
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and... 
Via Benzinga

Performance

YTD
+4.55%
+4.55%
1 Month
-9.09%
-9.09%
3 Month
-8.12%
-8.12%
6 Month
-7.86%
-7.86%
1 Year
+10.98%
+10.98%

More News

Read More
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
Via Benzinga
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
From Junshi Biosciences
Via GlobeNewswire
Friday Markets News
Via Talk Markets
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
From Bio-Thera Solutions, Ltd.
Via Business Wire
Summer Friday
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.